Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals' stock price increased significantly between April 8, 2025, and April 7, 2026. Key events impacting the stock include Ligand hosting an Investor Day in December 2025 and introducing its 2026 guidance. In February 2026, Ligand announced participation in a healthcare conference and reported its Fourth Quarter and Full Year 2025 financial results. In March 2026, Ligand participated in investor conferences, its CFO sold shares, Bank of America initiated coverage with a "Buy" rating, Ligand announced poster presentations at the American Academy of Dermatology Annual Meeting, and Ligand expanded its business development team. In April 2026, insider selling by a CLO and a director was reported.

The provided search results do not explicitly detail demand seasonality for Ligand Pharmaceuticals' products and services. Its revenue streams are tied to the commercial success and development milestones of its partners' drugs. Seasonality would likely be influenced by the collective performance and launch cycles of its numerous partnered pharmaceutical products rather than a direct seasonal demand for a specific Ligand offering.

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring and developing royalty-generating assets within the Healthcare sector and Biopharmaceuticals/Biotechnology industry. Its business model includes drug discovery, early-stage drug development, product reformulation, and strategic partnerships, generating revenue through royalties, license and milestone payments, and Captisol sales. As of 2024, Ligand's portfolio includes royalty rights to approximately 90 pharmaceutical products across various therapeutic areas, including the Captisol platform technology and royalty-generating products for cancer, kidney disease, infectious diseases, vaccines, osteoporosis, diabetes, and other therapeutic areas.

Ligand Pharmaceuticals is headquartered in Jupiter, Florida, U.S., and develops and licenses biopharmaceutical assets worldwide. Its institutional shareholders are primarily based in the United States, with smaller percentages from other countries. The company has alliances and licensing agreements with various pharmaceutical companies globally, including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International.

Ligand Pharmaceuticals generally maintains a positive brand reputation within the biopharmaceutical sector due to its successful royalty-generating model and strategic partnerships. The company's strong financial performance, strategic pivot to a royalty-focused model, analyst endorsements, and FDA-related milestones contribute positively to its reputation. Insider stock sales are closely watched but often seen as structured liquidity events.

Ligand Pharmaceuticals' equity is primarily held by institutional investors, mutual funds, and key insiders. Institutions hold a significant majority of the equity. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Janus Henderson Group Plc. Individuals hold a smaller percentage. Insiders hold a substantial portion, with Bvf Partners L P being the largest individual shareholder.